Back to top
more

Humacyte, Inc. (HUMA)

(Delayed Data from NSDQ)

$2.28 USD

2.28
5,793,581

-0.12 (-5.00%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $2.27 -0.01 (-0.44%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $2.4 in the latest trading session, marking a -1.23% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.53, signifying a -5.24% move from its prior day's close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $2.67 in the latest trading session, marking a -2.2% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.33, signifying a -3.72% move from its prior day's close.

Zacks Equity Research

Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $2.28 in the latest trading session, marking a -7.69% move from the prior day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.54, representing a -1.17% change from its previous close.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: Humacyte, Starbucks, Oracle in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $2.09, representing a -1.42% change from its previous close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know

by Zacks Equity Research

In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.19, marking a -1.79% move from the previous day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.36, signifying a +1.29% move from its prior day's close.

Zacks Equity Research

Is Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?

by Zacks Equity Research

The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of 47.37% and 2.45%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

by Zacks Equity Research

The latest trading day saw Humacyte, Inc. (HUMA) settling at $1.45, representing a +1.4% change from its previous close.

Zacks Equity Research

All You Need to Know About Humacyte, Inc. (HUMA) Rating Upgrade to Buy

by Zacks Equity Research

Humacyte, Inc. (HUMA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Humacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to Note

by Zacks Equity Research

Humacyte, Inc. (HUMA) reachead $1.48 at the closing of the latest trading day, reflecting a +0.68% change compared to its last close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) reachead $1.55 at the closing of the latest trading day, reflecting a +0.65% change compared to its last close.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed at $1.45 in the latest trading session, marking a -0.68% move from the prior day.

Zacks Equity Research

Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet

by Zacks Equity Research

The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?

Zacks Equity Research

Humacyte, Inc. (HUMA) Flat As Market Gains: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Humacyte, Inc. (HUMA) stood at $3.32, denoting no change from the preceding trading day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $2.99, signifying a -0.33% move from its prior day's close.

Zacks Equity Research

Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?

by Zacks Equity Research

Based on the average brokerage recommendation (ABR), Humacyte, Inc. (HUMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Slides as Market Rises: Facts to Know Before You Trade

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed the most recent trading day at $3.15, moving -1.56% from the previous trading session.

Zacks Equity Research

Humacyte, Inc. (HUMA) Falls More Steeply Than Broader Market: What Investors Need to Know

by Zacks Equity Research

In the most recent trading session, Humacyte, Inc. (HUMA) closed at $3.37, indicating a -1.75% shift from the previous trading day.

Zacks Equity Research

Humacyte, Inc. (HUMA) Suffers a Larger Drop Than the General Market: Key Insights

by Zacks Equity Research

Humacyte, Inc. (HUMA) closed the most recent trading day at $3.96, moving -1.25% from the previous trading session.

Zacks Equity Research

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Humacyte, Inc. (HUMA) concluded the recent trading session at $4.30, signifying a -1.6% move from its prior day's close.